Trial Profile
A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Ianalumab (Primary) ; Iscalimab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 08 Jan 2024 Planned End Date changed from 13 Sep 2024 to 24 Apr 2026.
- 08 Jan 2024 Planned primary completion date changed from 13 Sep 2024 to 24 Apr 2026.
- 15 Nov 2023 Results reporting safety and efficacy of ianalumab in patients with active SLE presented at the ACR Convergence 2023